Peptides are going to cure everything from spinal chord injuries to ALS, Alzheimer’s and Cancer
This is not a “$2B market”
This is a revolution of unprecedented magnitude
Looks like it’s finally happening… the FDA is now prepared to move at least 14 peptides to the Category 1 list which means US based compounding labs/pharmacies will be able to make and sell them for human consumption.
This is great for $HIMS because they own both 503a and 503b facilities. This move by the FDA will destroy the grey market (90% comes from China) which has exploded over the past few years.
Ironically, I placed my typical biweekly peptide order this morning… soon I’ll be spending this money with $HIMS as will millions of other people.
I’ll be a guest on the @HimsHouse podcast next week to discuss my 3+ year investment thesis on $HIMS and why I think peptides will play a major role in the next phase of growth for the company.
NFA.
DYOR.
*We own $HIMS at @FirstWaveFund and added to our position this morning which is our first add in the last couple weeks.
I'll be joining @HimsHouse in the next couple weeks to talk about $HIMS, my long-term investment thesis, my thoughts on the new $NVO partnership, why I'm still bullish on GLP1s, why I think peptides will be the next big growth driver/catalyst, why I'm excited about the recent acquisition of Eucalyptus, and what it will take for $HIMS to hit $100+ per share by the end of 2030.
With regards to peptides, here are my top 10 in alphabetical order:
1. BPC-157
2. CJC-1295
3. EPITALON
4. GHK-CU
5. MOTS-C
6. NAD+
7. RETATRUTIDE
8. SERMORELIN
9. TB-500
10. TESAMORELIN
Additional peptides that I'm still researching:
1. SEMAX
2. SELANK
3. DSIP
4. CARTALAX
You don't realise the extent to which peptides are central to society because you don't understand how the spike protein, which is now everywhere, suppresses the immune system and damages mitochondria.
We have a massive problem and $HIMS is uniquely positioned to fix it.
Today, we’re announcing a multi-year, multi generation strategic partnership with @OpenAI that puts AMD compute at the center of the global AI infrastructure buildout.
✅ 6GW of AI infrastructure
✅ Initial 1GW deployment of AMD Instinct MI450 series GPU capacity beginning 2H 2026
✅ Enabling very large-scale AI deployments and advancing the entire AI ecosystem
More here: https://t.co/hGA8zSA6sM
Everyone’s chasing $NVDA. I went all-in on $AMD.
Why?
Because AMD will 100X from here — just like I called $PLTR at $7.
The market’s asleep.
But Meta, OpenAI, and I know what’s coming.
AMD is going to disrupt NVIDIA.
Here’s the full thesis 🧠👇
🧵
We are disappointed to see Novo Nordisk management misleading the public.
In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.
We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first.
We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.